STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its ...
A new study has reported the effectiveness of raising glutathione levels in the blood through oral supplementation of liposomal glutathione. However, the team at Inid Research Labs that developed the ...
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. Twelve patients with refractory solid tumors were enrolled onto this three-period ...
Objective: Divalproex extended release (ER) tablets have lower bioavailability than conventional divalproex tablets. Objectives were to provide dose-increment justification for conversion of a patient ...
Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in rat and dog pharmacokinetic (PK) studies while significant ...
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, with a commercial ...
CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.
Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma ...
Divalproex is available as 125, 250 and 500mg tablets. Therefore, the possible divalproex total daily dosage regimens are in increments of 125mg. Table IV shows that all divalproex dosage regimens, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results